Skip to content
10-Q

Quarterly Report

Augmedix, Inc.

0001628280-24-022897

← back to feed
Filed
May 13, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 10, 2024 48.97M sh
Shares Diluted Q1 2024 · Mar 31, 2024 53.06M sh
Shares Diluted Q1 2024 · Mar 31, 2023 37.49M sh
Capex Q1 2024 · Mar 31, 2024 $568K
Capex Q1 2024 · Mar 31, 2023 $173K
Operating Cash Flow Q1 2024 · Mar 31, 2024 −$8.24M
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$6.22M
Cash And Equivalents Q1 2024 · Mar 31, 2024 $37.3M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $46.22M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $19.91M
Stockholders Equity Q1 2024 · Mar 31, 2024 $17.78M
Stockholders Equity Q1 2024 · Dec 31, 2023 $23.32M
Stockholders Equity Q1 2024 · Mar 31, 2023 −$3.19M
Stockholders Equity Q1 2024 · Dec 31, 2022 $1.47M
Current Liabilities Q1 2024 · Mar 31, 2024 $24.53M
Current Liabilities Q1 2024 · Dec 31, 2023 $23.62M
Total Liabilities Q1 2024 · Mar 31, 2024 $41.78M
Total Liabilities Q1 2024 · Dec 31, 2023 $43.39M
Current Assets Q1 2024 · Mar 31, 2024 $49.97M
Current Assets Q1 2024 · Dec 31, 2023 $56.82M
Total Assets Q1 2024 · Mar 31, 2024 $59.56M
Total Assets Q1 2024 · Dec 31, 2023 $66.71M
Eps Diluted Q1 2024 · Mar 31, 2024 −$0.12
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.14
Eps Basic Q1 2024 · Mar 31, 2024 −$0.12
Eps Basic Q1 2024 · Mar 31, 2023 −$0.14
Sga Expense Q1 2024 · Mar 31, 2024 $5.35M
Sga Expense Q1 2024 · Mar 31, 2023 $4.21M
Rd Expense Q1 2024 · Mar 31, 2024 $3.83M
Rd Expense Q1 2024 · Mar 31, 2023 $2.71M
Net Income Q1 2024 · Mar 31, 2024 −$6.5M
Net Income Q1 2024 · Mar 31, 2023 −$5.24M
Operating Income Q1 2024 · Mar 31, 2024 −$6.4M
Operating Income Q1 2024 · Mar 31, 2023 −$5.09M
Gross Profit Q1 2024 · Mar 31, 2024 $6.34M
Gross Profit Q1 2024 · Mar 31, 2023 $4.39M
Revenue Q1 2024 · Mar 31, 2024 $13.47M
Revenue Q1 2024 · Mar 31, 2023 $9.63M